Journal Article

Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective

V. Heinemann, K. Heinrich, W. G. Kunz, A. Mock, J. Kumbrink, C. B. Westphalen, M. Haas, S. Boeck, A. Jung, Steffen Ormanns, S. Corradini, D. Roessler, L. Weiss, M. Rudelius, G. Beyer, K. Dorman, M. von Bergwelt-Baildon, D. Zhang, K. Hasselmann, L. Heinzerling, K. Rühlmann, F. Klauschen

2023

Overview

Purpose For patients with cancer of unknown primary (CUP), treatment options are limited. Precision oncology, the interplay of comprehensive genomic profiling (CGP) and targeted therapies, aims to offer additional treatment options to patients with advanced and hard-to-treat cancers. We aimed to highlight the use of a molecular tumor board (MTB) in the therapeutic management of CUP patients. Methods In this single-center observational study, CUP patients, presented to the MTB of the Comprehensive Cancer Center Munich LMU, a tertiary care center, were analyzed retrospectively. Descriptive statistics were applied to describe relevant findings. Results Between June 2016 and February 2022, 61 patients with unfavorable CUP were presented to the MTB, detected clinically relevant variants in 74% (45/61) of patients, of which 64% (29/45) led to therapeutic recommendation. In four out of 29 patients (14%), the treatment recommendations were implemented, unfortunately without resulting in clinical benefit. Reasons for not following the therapeutic recommendation were mainly caused by the physicians’ choice of another therapy (9/25, 36%), especially in the context of worsening of general condition, lost to follow-up (7/25, 28%) and death (6/25, 24%). Conclusion CGP and subsequent presentation to a molecular tumor board led to a high rate of therapeutic recommendations in patients with CUP. Recommendations were only implemented at a low rate; however, late GCP diagnostic and, respectively, MTB referral were found more frequent for the patients with implemented treatment. This contrast underscores the need for early implementation of CGP into the management of CUP patients.

• Publisher: Springer Science and Business Media LLC,Springer Berlin Heidelberg,Springer Nature B.V
• Subject: Cancer / Cancer Research / death / descriptive statistics / Disease management / genomics / Hematology / Humans / Internal Medicine / Medical Oncology / Medicine / Medicine & Public Health / neoplasms / Neoplasms, Unknown Primary / Neoplasms, Unknown Primary - diagnosis / Neoplasms, Unknown Primary - genetics / Neoplasms, Unknown Primary - therapy / observational studies / Oncology / Patients / Precision Medicine / Precision Medicine - methods / Retrospective Studies / therapeutics / Tumors